Mizuho lifts target to USD 700 for Medpace stock

Published on 10/17/2026 at 21:58 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Medpace reports results on October 21, 2026. Medpace stock costs USD 618.47 on October 16, 2026, down 1.61 percent versus Nasdaq's prior close.

Mizuho target leads valuation

Mizuho lifted its Medpace target to USD 700.00 on October 7, 2026.
Medpace is scheduled to report third-quarter results on October 21, 2026.
Medpace stock last stood at USD 618.47 on Nasdaq on October 16, 2026 at 4:00 p.m. ET, down 1.61 percent versus the prior close of October 15, 2026.
Medpace traded at a P/E ratio of 36.23 as of October 16, 2026.

MEDP, US58506Q1094, Illustration mit AI erstellt.

Mizuho raised its Medpace price target from USD 665.00 to USD 700.00 on October 7, 2026, according to Markets Insider. The new target stands 13.18 percent above Medpace's Nasdaq price of USD 618.47 on October 16, 2026.

Results date sets the next marker

Medpace is scheduled to report third-quarter 2026 results after the market closes on October 21, 2026, with the earnings call set for October 22, 2026. The date appears on the company's investor relations page.

MarketBeat reported on October 14, 2026 that analysts expected third-quarter revenue of USD 714.47 million and earnings per share of USD 4.44. The same report placed the consensus target at USD 607.73, below Mizuho's USD 700.00 target, showing a wide spread in published expectations.

Price remains below the yearly high

Medpace's Nasdaq price was USD 618.47 at 4:00 p.m. ET on October 16, 2026, down USD 10.13 or 1.61 percent from the prior close. The 52-week range was USD 373.00 to USD 677.90, leaving the stock 8.77 percent below its high and 65.81 percent above its low.

Trading volume reached 297,570 shares on October 16, 2026, compared with an average volume of 272,673 shares. That places the session volume 9.11 percent above the average.

Valuation and clinical research peers

Medpace had a market capitalization of USD 17.3 billion and a P/E ratio of 36.23 as of October 16, 2026. The company operates as a contract research organization serving biotechnology, pharmaceutical and medical device clients.

Comparison with peers

MEDP (Nasdaq, USD): minus 1.61 percent, P/E 36.23, market capitalization USD 17.3 billion
IQVIA Holdings (NYSE, USD): minus 1.53 percent, P/E 33.11, market capitalization USD 43.9 billion
Charles River Laboratories (NYSE, USD): minus 1.99 percent, P/E minus 61.89, market capitalization USD 14.5 billion